|
Rank |
Drug Name (Brand) |
Class |
Reported number of persons prescribed |
|
1 |
Sertraline hydrochloride (Zoloft) |
SSRI antidepressant |
6,223,000 |
|
2 |
Citalopram hydrobromide (Celexa) |
SSRI antidepressant |
5,403,000 |
|
3 |
Alprazolam (Xanax) |
Benzodiazepine |
5,259,000 |
|
4 |
Zolpidem tartrate (Ambien) |
Hypnotic |
4,865,000 |
|
5 |
Fluoxetine hydrochloride (Prozac) |
SSRI antidepressant |
4,259,000 |
|
6 |
Trazodone hydrochloride (Desyrel) |
SARI antidepressant |
4,166,000 |
|
7 |
Clonazepam (Klonopin) |
Benzodiazepine |
3,273,000 |
|
8 |
Lorazepam (Ativan) |
Benzodiazepine |
3,165,000 |
|
9 |
Escitalopram oxalate (Lexapro) |
SSRI antidepressant |
3,065,000 |
|
10 |
Duloxetine hydrochloride (Cymbalta) |
SNRI antidepressant |
2,709,000 |
At the Becker's Fall Behavioral Health Summit, taking place November 4–5 in Chicago, behavioral health leaders and executives will explore strategies for expanding access to care, integrating services, addressing workforce challenges and leveraging innovation to improve outcomes across the behavioral health continuum. Apply for complimentary registration now.
